Cancer Nsclc Articles & Analysis
9 articles found
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic ...
The two antigen-binding arms respectively bind to two antigens on the surface of cancer cells, which can effectively enhance the binding specificity and targeting of the antibody to cancer cells and reduce side effects such as off-target. ...
Different from the approved indications of Trodelvy, Dato-DXd plans to use advanced non-small cell lung cancer (NSCLC) as the first indication. In addition to single-target Trop-2 ADCs, some companies are also deploying dual-target ADCs. ...
However, understanding the roles of CADM molecules in tumor immune escape may offer valuable insights for developing novel immunotherapeutic strategies to overcome immune evasion and enhance the body's ability to recognize and eliminate cancer cells. CADM1 and Lung Cancer CADM1 is often downregulated or lost in lung cancer, particularly in ...
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a relatively rare and dangerous subtype, with patients suffering from a high incidence rate of brain metastases. ...
Abstract Background Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence. Materials and Methods We analyzed gene expression in frozen lung ...
Metastatic melanoma (Stage IV) has 22.5% five year survival. Non-small cell lung cancer (NSCLC) is a major unmet medical need that accounts for 85% of pulmonary malignancies and effects approximately 450,000 individuals. ...
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this ...
Over time, genetic research have recognized a number of genetic danger variants related to neurodegenerative problems and helped reveal new organic pathways and genes of curiosity. Nevertheless, genetic danger variants generally reside in non-coding areas and should regulate distant genes reasonably than the closest gene, in addition to a gene’s interplay companions in organic networks. ...